Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ELOS's Cash to Debt is ranked higher than
94% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ELOS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ELOS' s 10-Year Cash to Debt Range
Min: 65.7  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.74
ELOS's Equity to Asset is ranked higher than
68% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ELOS: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
ELOS' s 10-Year Equity to Asset Range
Min: 0.61  Med: 0.76 Max: 0.89
Current: 0.74
0.61
0.89
F-Score: 6
Z-Score: 4.02
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -1.04
ELOS's Operating margin (%) is ranked lower than
56% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ELOS: -1.04 )
Ranked among companies with meaningful Operating margin (%) only.
ELOS' s 10-Year Operating margin (%) Range
Min: -249.56  Med: -0.54 Max: 44.31
Current: -1.04
-249.56
44.31
Net-margin (%) -2.00
ELOS's Net-margin (%) is ranked lower than
55% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ELOS: -2.00 )
Ranked among companies with meaningful Net-margin (%) only.
ELOS' s 10-Year Net-margin (%) Range
Min: -243.89  Med: 2.77 Max: 47.2
Current: -2
-243.89
47.2
ROE (%) -2.38
ELOS's ROE (%) is ranked lower than
57% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. ELOS: -2.38 )
Ranked among companies with meaningful ROE (%) only.
ELOS' s 10-Year ROE (%) Range
Min: -186.63  Med: 1.56 Max: 95.92
Current: -2.38
-186.63
95.92
ROA (%) -1.79
ELOS's ROA (%) is ranked lower than
52% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. ELOS: -1.79 )
Ranked among companies with meaningful ROA (%) only.
ELOS' s 10-Year ROA (%) Range
Min: -120.76  Med: 1.29 Max: 48.19
Current: -1.79
-120.76
48.19
ROC (Joel Greenblatt) (%) -6.24
ELOS's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. ELOS: -6.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ELOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -397.3  Med: 20.17 Max: 1877.32
Current: -6.24
-397.3
1877.32
Revenue Growth (3Y)(%) 2.40
ELOS's Revenue Growth (3Y)(%) is ranked lower than
54% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ELOS: 2.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ELOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 11.40 Max: 188.4
Current: 2.4
0
188.4
EPS Growth (3Y)(%) -54.00
ELOS's EPS Growth (3Y)(%) is ranked lower than
95% of the 176 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ELOS: -54.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ELOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -64  Med: -24.65 Max: 98.2
Current: -54
-64
98.2
» ELOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ELOS Guru Trades in Q3 2014

Steven Cohen 60,000 sh (New)
Charles Brandes 2,300,020 sh (+10.70%)
Chuck Royce 987,059 sh (unchged)
Steven Cohen 66,500 sh (unchged)
Mario Gabelli 24,000 sh (unchged)
Jim Simons 494,180 sh (-3.80%)
Seth Klarman 2,994,610 sh (-25.13%)
» More
Q4 2014

ELOS Guru Trades in Q4 2014

Jim Simons 534,967 sh (+8.25%)
Charles Brandes 2,338,530 sh (+1.67%)
Mario Gabelli 24,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 881,759 sh (-10.67%)
Seth Klarman 2,416,310 sh (-19.31%)
» More
Q1 2015

ELOS Guru Trades in Q1 2015

Jim Simons 838,780 sh (+56.79%)
Mario Gabelli 24,000 sh (unchged)
Seth Klarman Sold Out
Chuck Royce 562,359 sh (-36.22%)
Charles Brandes 866,320 sh (-62.95%)
Seth Klarman 1,127,160 sh (-53.35%)
» More
Q2 2015

ELOS Guru Trades in Q2 2015

Jim Simons 931,703 sh (+11.08%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 437,559 sh (-22.19%)
Charles Brandes 570,430 sh (-34.15%)
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 15.70
ELOS's Forward P/E is ranked higher than
72% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.15 vs. ELOS: 15.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.50
ELOS's P/B is ranked higher than
77% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. ELOS: 1.50 )
Ranked among companies with meaningful P/B only.
ELOS' s 10-Year P/B Range
Min: 0.58  Med: 1.67 Max: 10.23
Current: 1.5
0.58
10.23
P/S 1.26
ELOS's P/S is ranked higher than
71% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. ELOS: 1.26 )
Ranked among companies with meaningful P/S only.
ELOS' s 10-Year P/S Range
Min: 1.08  Med: 2.35 Max: 15.69
Current: 1.26
1.08
15.69
PFCF 232.96
ELOS's PFCF is ranked lower than
95% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 32.61 vs. ELOS: 232.96 )
Ranked among companies with meaningful PFCF only.
ELOS' s 10-Year PFCF Range
Min: 4.32  Med: 20.20 Max: 1090
Current: 232.96
4.32
1090
POCF 58.26
ELOS's POCF is ranked lower than
84% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 21.13 vs. ELOS: 58.26 )
Ranked among companies with meaningful POCF only.
ELOS' s 10-Year POCF Range
Min: 4.15  Med: 20.14 Max: 541.5
Current: 58.26
4.15
541.5
Current Ratio 2.90
ELOS's Current Ratio is ranked higher than
56% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. ELOS: 2.90 )
Ranked among companies with meaningful Current Ratio only.
ELOS' s 10-Year Current Ratio Range
Min: 2.63  Med: 4.05 Max: 10.72
Current: 2.9
2.63
10.72
Quick Ratio 2.24
ELOS's Quick Ratio is ranked higher than
56% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ELOS: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
ELOS' s 10-Year Quick Ratio Range
Min: 2.07  Med: 3.71 Max: 10.39
Current: 2.24
2.07
10.39
Days Inventory 111.54
ELOS's Days Inventory is ranked higher than
59% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 130.22 vs. ELOS: 111.54 )
Ranked among companies with meaningful Days Inventory only.
ELOS' s 10-Year Days Inventory Range
Min: 24.89  Med: 104.89 Max: 205.18
Current: 111.54
24.89
205.18
Days Sales Outstanding 83.50
ELOS's Days Sales Outstanding is ranked lower than
61% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.40 vs. ELOS: 83.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELOS' s 10-Year Days Sales Outstanding Range
Min: 50.5  Med: 81.73 Max: 120.06
Current: 83.5
50.5
120.06

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.65
ELOS's Price/Net Current Asset Value is ranked higher than
86% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 6.85 vs. ELOS: 2.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ELOS' s 10-Year Price/Net Current Asset Value Range
Min: 0.86  Med: 2.88 Max: 8.12
Current: 2.65
0.86
8.12
Price/Tangible Book 1.81
ELOS's Price/Tangible Book is ranked higher than
78% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.09 vs. ELOS: 1.81 )
Ranked among companies with meaningful Price/Tangible Book only.
ELOS' s 10-Year Price/Tangible Book Range
Min: 0.71  Med: 2.13 Max: 7.9
Current: 1.81
0.71
7.9
Price/Median PS Value 0.52
ELOS's Price/Median PS Value is ranked higher than
88% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. ELOS: 0.52 )
Ranked among companies with meaningful Price/Median PS Value only.
ELOS' s 10-Year Price/Median PS Value Range
Min: 0.49  Med: 1.06 Max: 6.01
Current: 0.52
0.49
6.01
Earnings Yield (Greenblatt) (%) -1.23
ELOS's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. ELOS: -1.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ELOS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.31  Med: 5.90 Max: 8327.2
Current: -1.23
-1.31
8327.2

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 287 319
EPS($) 0.33 0.57
EPS without NRI($) 0.33 0.57

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FGD.Germany,
Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets innovative aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company's proprietary ELOS technology, which combines optical and electrical energy, enhances the user's ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. Its patent portfolio (including patents held by subsidiaries) consisted of 140 issued U.S. patents.The Company's trademarks include Syneron, Elos, Candela, Ultrashape, Litetouch, VelaShape, VelaSmooth, Sublative, eTwo, eMax, ePRIME, eLase, elosPlus, Elure, Motif, Co2re, eMatrix, Matrix IR, Matrix RF, Refirme. It competes with large pharmaceutical companies that have entered the aesthetic device market, such as Valeant Pharmaceuticals International Inc. (which acquired Solta Medical Inc. in 2014), Merz Pharma Group (which acquired Ulthera, Inc. in 2014) and Actevis PLC (which acquired Allergan, Inc. in 2014). Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and hyaluronic acid injections, face lifts, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company's products are medical devices and cosmetics subject to extensive and rigorous regulation by the FDA, as well as other U.S. and foreign regulatory bodies.
» More Articles for ELOS

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
comment on ELOS Jan 31 2012 
note on ELOS Oct 08 2011 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
comment on ELOS Aug 20 2011 
comment on ELOS Aug 20 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 16 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 12 2009 

More From Other Websites
Edited Transcript of ELOS earnings conference call or presentation 4-Aug-15 12:30pm GMT Aug 04 2015
Q2 2015 Syneron Medical Ltd Earnings Release - Before Market Open Aug 04 2015
Syneron Medical reports 2Q loss Aug 04 2015
Syneron Medical reports 2Q loss Aug 04 2015
Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 Aug 04 2015
Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser Jul 27 2015
Syneron Medical to Report Second Quarter 2015 Financial Results on August 4, 2015 Jul 17 2015
Study Published In May Issue Of Journal Of Dermatologic Surgery Demonstrates Significant Improvement... Jun 25 2015
Study Published In May Issue Of Journal Of Dermatologic Surgery Demonstrates Significant Improvement... Jun 25 2015
Syneron and Viora Announce Settlement Agreement of Business and Patent Litigations Jun 04 2015
Falling Earnings Estimates Signal Weakness Ahead for Syneron Medical (ELOS) - Tale of the Tape Jun 01 2015
What Falling Estimates & Price Mean for Syneron Medical (ELOS) - Tale of the Tape May 29 2015
Syneron Candela Unveils Larsa Pippen As Newest UltraShape Brand Champion May 27 2015
Syneron Medical reports 1Q loss May 13 2015
Syneron Medical reports 1Q loss May 13 2015
Syneron Medical Reports Revenue of $63.4 Million for the First Quarter 2015 May 13 2015
Syneron Medical to Report First Quarter 2015 Financial Results on May 13, 2015 Apr 29 2015
Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Treatment of Pigmented... Apr 20 2015
Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Treatment of Pigmented... Apr 20 2015
Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Mar 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK